Literature DB >> 8876223

Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.

C Liu1, E Adamson, D Mercola.   

Abstract

The early growth response 1 (EGR-1) gene product is a transcription factor with role in differentiation and growth. We have previously shown that expression of exogenous EGR-1 in various human tumor cells unexpectedly and markedly reduces growth and tumorigenicity and, conversely, that suppression of endogenous Egr-1 expression by antisense RNA eliminates protein expression, enhances growth, and promotes phenotypic transformation. However, the mechanism of these effects remained unknown. The promoter of human transforming growth factor beta 1 (TGF-beta 1) contains two GC-rich EGR-1 binding sites. We show that expression of EGR-1 in human HT-1080 fibrosarcoma cells uses increased secretion of biologically active TGF-beta 1 in direct proportion (rPearson = 0.96) to the amount of EGR-1 expressed and addition of recombinant human TGF-beta 1 is strongly growth-suppressive for these cells. Addition of monoclonal anti-TGF-beta 1 antibodies to EGR-1-expressing HT-1080 cells completely reverses the growth inhibitory effects of EGR-1. Reporter constructs bearing the EGR-1 binding segment of the TGF-beta 1 promoter was activated 4- to 6-fold relative to a control reporter in either HT-1080 cells that stably expressed or parental cells cotransfected with an EGR-1 expression vector. Expression of delta EGR-1, a mutant that cannot interact with the corepressors, nerve growth factor-activated factor binding proteins NAB1 and NAB2, due to deletion of the repressor domain, exhibited enhanced transactivation of 2- to 3.5-fold over that of wild-type EGR-1 showing that the reporter construct reflected the appropriate in vivo regulatory context. The EGR-1-stimulated transactivation was inhibited by expression of the Wilms tumor suppressor, a known specific DNA-binding competitor. These results indicate that EGR-1 suppresses growth of human HT-1080 fibrosarcoma cells by induction of TGF-beta 1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876223      PMCID: PMC38144          DOI: 10.1073/pnas.93.21.11831

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  A biological role for Egr-1 in cell survival following ultra-violet irradiation.

Authors:  R P Huang; E D Adamson
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

2.  Transforming growth factor beta and cell cycle regulation.

Authors:  M G Alexandrow; H L Moses
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

3.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

Authors:  K Polyak; M H Lee; H Erdjument-Bromage; A Koff; J M Roberts; P Tempst; J Massagué
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

Review 4.  Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors.

Authors:  A Gashler; V P Sukhatme
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1995

5.  WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.

Authors:  K E Nichols; G G Re; Y X Yan; A J Garvin; D A Haber
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.

Authors:  B R Dey; V P Sukhatme; A B Roberts; M B Sporn; F J Rauscher; S J Kim
Journal:  Mol Endocrinol       Date:  1994-05

7.  Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells.

Authors:  L Sun; G Wu; J K Willson; E Zborowska; J Yang; I Rajkarunanayake; J Wang; L E Gentry; X F Wang; M G Brattain
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

8.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Authors:  S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

9.  Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription.

Authors:  M W Russo; B R Sevetson; J Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

10.  Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product.

Authors:  H Nakagama; G Heinrich; J Pelletier; D E Housman
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

View more
  40 in total

1.  COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site.

Authors:  C Pipaón; S Y Tsai; M J Tsai
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Expression of Egr-1 in late stage emphysema.

Authors:  W Zhang; S D Yan; A Zhu; Y S Zou; M Williams; G C Godman; B M Thomashow; M E Ginsburg; D M Stern; S F Yan
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

4.  The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia.

Authors:  S A Friedle; V M Brautigam; M Nikodemova; M L Wright; J J Watters
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

5.  4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

Authors:  Seongseok Yun; Nicole D Vincelette; Katherine L B Knorr; Luciana L Almada; Paula A Schneider; Kevin L Peterson; Karen S Flatten; Haiming Dai; Keith W Pratz; Allan D Hess; B Douglas Smith; Judith E Karp; Andrea E Wahner Hendrickson; Martin E Fernandez-Zapico; Scott H Kaufmann
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

6.  Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.

Authors:  Yifan Lu; Tong Li; Hamid Y Qureshi; Dong Han; Hemant K Paudel
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

7.  Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.

Authors:  Dawei Yuan; Kang Li; Kun Zhu; Rong Yan; Chengxue Dang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 8.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

9.  Gene expression profiling in skeletal muscle of Holstein-Friesian bulls with single-nucleotide polymorphism in the myostatin gene 5'-flanking region.

Authors:  Tomasz Sadkowski; Michał Jank; Lech Zwierzchowski; Eulalia Siadkowska; Jolanta Oprzadek; Tomasz Motyl
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

10.  Novel mutants of NAB corepressors enhance activation by Egr transactivators.

Authors:  J Svaren; B R Sevetson; T Golda; J J Stanton; A H Swirnoff; J Milbrandt
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.